Aclaris Capital Lease Obligations from 2010 to 2025
| ACRS Stock | USD 1.59 0.03 1.85% |
Capital Lease Obligations | First Reported 2019-03-31 | Previous Quarter 310 K | Current Value 426 K | Quarterly Volatility 146.3 K |
Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 766.6 K, Interest Expense of 3.2 M or Selling General Administrative of 21.5 M, as well as many indicators such as Price To Sales Ratio of 9.73, Dividend Yield of 0.0 or PTB Ratio of 0.7. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.
Aclaris | Capital Lease Obligations |
Latest Aclaris Therapeutics' Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Aclaris Therapeutics over the last few years. Aclaris Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Aclaris Therapeutics asset purchases. For example, Aclaris Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Aclaris Therapeutics control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Aclaris Therapeutics' Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aclaris Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Aclaris Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 366,553 | |
| Geometric Mean | 288,047 | |
| Coefficient Of Variation | 65.54 | |
| Mean Deviation | 224,553 | |
| Median | 426,000 | |
| Standard Deviation | 240,230 | |
| Sample Variance | 57.7B | |
| Range | 551K | |
| R-Value | 0.80 | |
| Mean Square Error | 22.3B | |
| R-Squared | 0.64 | |
| Significance | 0.0002 | |
| Slope | 40,331 | |
| Total Sum of Squares | 865.7B |
Aclaris Capital Lease Obligations History
About Aclaris Therapeutics Financial Statements
Aclaris Therapeutics shareholders use historical fundamental indicators, such as Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aclaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aclaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 489.9 K | 594.9 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.